美股市场个股详情
NUVL Nuvalent
- 66.860
- +0.790+1.20%
收盘价 04/26 16:00 (美东)
- 65.220
- -1.640-2.45%
盘后 19:16 (美东)
43.15亿总市值-30811市盈率TTM
66.895最高价65.080最低价23.03万股成交量66.230今开66.070昨收1532.60万成交额0.69%换手率亏损市盈率(静)6454.22万总股本89.39052周最高6.16市净率22.28亿流通值35.29052周最低--股息TTM3332.26万流通股89.390历史最高--股息率TTM2.75%振幅7.090历史最低66.559平均价1股每手
关于Nuvalent公司
Nuvalent, Inc.是一家临床阶段的生物制药公司，专注于为癌症患者创造精确靶向治疗。其产品线包括ROS1 NSCLC、ALK NSCLC和HER2 NSCLC。
公司介绍
公司代码NUVL
公司名称Nuvalent
上市日期2021/07/29
发行价格17.00
成立日期2017
CEODr. James R. Porter, PhD
所属市场纳斯达克
员工数量92
证券类型海外普通股
年结日12-31
公司地址One Broadway,14th floor
城市Cambridge
省份马萨诸塞州
国家美国
邮编02142
电话1-857-357-7000
董事高管
- 姓名
- 职务
- 年薪
- Dr. Matthew Shair, PhD
- Director and Scientific Founder
- 36.04万
- Dr. James R. Porter, PhD
- Director, Chief Executive Officer and President
- 521.46万
- Alexandra Balcom, M.B.A.
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 201.98万
- Darlene Noci, A.C.I.S.
- Chief Development Officer
- --
- Dr. Deborah Miller, J.D.,PhD
- Chief Legal Officer and Secretary
- --
- Dr. Christopher D. Turner, M.D.
- Chief Medical Officer
- 207.98万
- Dr. Sapna Srivastava, PhD
- Independent Director
- 17.19万
- Dr. Joseph Pearlberg, M.D.,PhD
- Independent Director
- 16.84万
- Dr. Cameron Wheeler, PhD
- Independent Director
- 18.17万
- Anna Protopapas
- Independent Director
- 55.37万
- Dr. Emily Drabant Conley, PhD
- Independent Director
- 52.40万
- Dr. Michael L. Meyers, M.D.,PhD
- Independent Director
- 36.68万
- Dr. D. Gary Gilliland, M.D.,PhD
- Independent Director
- 17.42万
- Dr. Andrew A. F. Hack, M.D.,PhD
- Independent Director
- 17.13万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅